NCT01941511View on ClinicalTrials.gov

A Study to Evaluate the Effect of IV Doses of GMI-1070 on Qtc Intervals in Healthy African-American Adult Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

August 31, 2014

Study Completion Date

August 31, 2014

Conditions
Healthy
Interventions
DRUG

Rivipansel

Subjects will receive in a randomized sequence rivipansel 4gA IV, moxifloxacin 400 mg, and placebo IV.

Trial Locations (1)

78209

Pfizer Investigational Site, San Antonio

All Listed Sponsors
lead

GlycoMimetics Incorporated

INDUSTRY

NCT01941511 - A Study to Evaluate the Effect of IV Doses of GMI-1070 on Qtc Intervals in Healthy African-American Adult Subjects | Biotech Hunter | Biotech Hunter